This study provides the first comprehensive pan-cancer analysis of DSN1, revealing its diverse roles in tumorigenesis and progression, and establishing its potential as a promising biomarker for immunotherapy and drug sensitivity prediction (Table 1, Fig. S6). This evidence concerns the gene DSN1 and cancer.